Ovarian cancer
Not recruitingPhase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression
Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression
- Disease:Ovarian cancer
- Substances:INCB123667Paclitaxel+3
Spain- Participants:18–64 years · 65+ years
- Substances:INCB123667
- Sponsor:Incyte Corp.











